EC Clinical and Medical Case Reports

Hyperglycemia is often detected in patients with COVID-19. At the same time, persons with this disorder have longer hospitalization periods and an increased risk of an unfavorable outcome. Diabetes mellitus occupies one of the leading positions in the structure of the incidence of a new coronavirus infection. During infection with MERS-CoV-2, blood sugar control significantly worsens not only in patients with impaired carbohydrate metabolism, but also in people without previous glucose metabolism disorders. In this paper, possible mechanisms of hyperglycemia development in COVID-19 are considered.

Keywords: COVID-19; SARS-CoV-2; Hyperglycemia; Diabetes Mellitus

1. World Health Organization. Coronavirus disease 2019 (‎‎COVID-19)‎‎ Situation report (2020). https://apps.who.int/iris/handle/10665/331475
2. Yakovlev AYu., et al. “Metabolic therapy and its effect on respiratory lung function in patients with severe COVID-19”. Kazan Medical Journal3 (2022): 364-372.
3. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet10223 (2020): 497-506.
4. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet10229 (2020): 1054-1062.
5. Kalmykova ZA., et al. “Hyperglycemia and possible mechanisms of β-cell damage in patients with COVID-19”. Diabetes Mellitus3 (2020): 229-234.
6. Mareev VYu., et al. “Pulse therapy with steroid hormones in patients with Coronavirus pneumonia (COVID-19), systemic inflammation and risk of venous thrombosis and thromboembolism (Putnik study)”. Cardiology6 (2020): 15-29.
7. Bode B., et al. “Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States”. Journal of Diabetes Science and Technology4 (2020): 813-821.
8. Lacobellis G., et al. “Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes”. Diabetes Research and Clinical Practice 164 (2020): 108-185.
9. Thaweerat W. “Current evidence on pancreatic involvement in SARS-CoV-2 infection”. Pancreatology5 (2020): 1013-1014.
10. Batsigov HA and Sayfutdinov RG. “Stress hyperglycemia in assessing the severity and prognosis of the course of AMI”. Palliative Medicine and Rehabilitation 2 (2005): 37-38.
11. Batsigov HA. “Stress hyperglycemia and leukocytosis in assessing the severity and prognosis of acute myocardial infarction: abstract of the dissertation of the Candidate of Medical Sciences”. Kazan (2009): 23.
12. Saifutdinov RG., et al. “The phenomenon of transient stress hyperglycemia in acute myocardial infarction, its structure and prognostic”. Cardiology Commonwealth of Independent States1 (2003): 252-253.
13. Hoffmann M., et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell2 (2020): 271-280.
14. Zou X., et al. “Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection”. Frontiers in Medicine2 (2020): 185-192.
15. Rybakova MG., et al. “Pathomorphology of organs in COVID-19”. Evolution of the COVID-19 Pandemic (2021): 311-348.
16. Yang JK., et al. “Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes”. Acta Diabetologica3 (2010): 193-199.
17. Yao XH., et al. “A pathological report of three COVID-19 cases by minimal invasive autopsies”. Chinese Journal of Pathology5 (2020): 411-417.
18. Selimov AYu., et al. “Glucose metabolism disorders in patients taking GCS: features of clinical manifestations and correction”. Kuban Scientific Medical Bulletin1 (2019): 209-218.
19. Sathish T., et al. “Preexisting prediabetes and the severity of COVID-19”. Primary Care Diabetes1 (2021): 28-29.
20. Bornstein SR., et al. “Practical recommendations for the management of diabetes in patients with COVID-19”. The Lancet Diabetes and Endocrinology6 (2020): 546-550.
21. Tucker ME. “Checklist to Manage Hyperglycemia, DKA in Severe COVID-19”. Medscape's Coronavirus Resource Center9 (2020): 3-4.
22. Wang A., et al. “Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed”. Diabetes Research and Clinical Practice (2020): 108-118.
23. Zhou J and Tan J. “Diabetes patients with COVID-19 need better care”. Metabolism (2020): 154-216.
24. Iqbal A., et al. “Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans”. The Journal of Clinical Endocrinology and Metabolism4 (2019): 1187-1199.
25. Sathish T., et al. “Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis”. Diabetes, Obesity and Metabolism3 (2021): 870-874.
26. Demidova TYu and Plahotnik VM. “A new paradigm of early prevention of cardiovascular diseases”. Medical Council of India 14 (2021): 124-132.
27. Hostalek U. “Global epidemiology of prediabetes – present and future perspectives”. Clinical Diabetes and Endocrinology 5 (2019): 5-12.
28. Sosibo AM and Khathi A. “Pre-diabetes and COVID-19, could we be missing the silent killer?” Experimental Biology and Medicine4 (2021): 369-370.
29. Strongin LG., et al. “Features of the course of COVID-19 in comorbid patients with obesity and dysglycemia”. Russian Cardiological Journal3 (2022): 48-35.
30. Ensuring the safety of parenteral nutrition. “Federal State Budgetary Institution "Clinical Hospital No. 1" (Volynskaya) of the Presidential Administration of the Russian Federation (2021). https://volynka.ru/Articles/Text/1340
31. Jeejeebhoy K. “Enteral and parenteral nutrition: Evidence-based approach”. Proceedings of the Nutrition Society3 (2021): 399-402.
32. Sabirov IS., et al. “Modern methods of slowing the progression of chronic kidney disease in type 2 diabetes”. Bulletin of Modern Clinical Medicine4 (2020): 76-85.
33. Sabirov IS., et al. “Factors of cardiovascular risk in new coronavirus infection (COVID-19) on the background of diabetes”. Bulletin of the Kyrgyz-Russian Slavic University5 (2021): 68-78.
34. Trigolosova IV. “Steroid-induced DM”. Russian Medical Journal 1 (2016): 54-56.
35. Ostroumova O.D., et al. “Drug-induced hyperglycemia”. Clinical Pharmacology and Therapy2 (2019): 61-69.
36. Sabirov IS., et al. “Steroid-induced diabetes: a modern view of the problem and the possibilities of therapy”. The Scientific Heritage 70-2 (2021): 35-39.
37. Nozdrachev AD and Maslyukov PM. “Neuropeptide Y and the autonomic nervous system”. Journal of Evolutionary Biochemistry and Physiology2 (2011): 105-112.
38. Galstyan GR., et al. “Evolution of glucagon-like peptide–1 receptor agonists in the therapy of type 2 diabetes”. Diabetes Mellitus4 (2017): 286-298.
39. Raalte DH., et al. “Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men”. European Journal of Endocrinology 162 (2010): 729-735.
40. Hansen KB., et al. “Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects”. Journal of Clinical Endocrinology and Metabolism7 (2010): 3309-3317.
41. Valeeva FV and Nurullina GI. “Diagnostic value of c–peptide and modified HOMA indices in various disorders of carbohydrate metabolism against the background of glucocorticoid therapy”. Medical Bulletin of the South of Russia1 (2018): 23-31.
42. Donihi AC., et al. “Prevalence and predictors of corticosteroid related hyperglycemia in hospitalized patients”. Endocrine Practice4 (2006): 358-362.
43. Gurwitz JH., et al. “Glucocorticoids and the risk for initiation of hypoglycemic therapy”. International Archives of Internal Medicine1 (1994): 97-101.